CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Losses	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		97,377,121
Beginning balance at Dec. 31, 2023	$ 133,071	$ 2	$ 624,414	$ (15)	$ (491,330)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		22,560,001
Issuance of common stock	132,055		132,055
Issuance of pre-funded warrants, net of issuance costs of $1.2 million	18,800		18,800
Issuances of common stock under the employee stock purchase plan (in shares)		74,488
Issuances of common stock under the employee stock purchase plan	436		436
Issuance of common stock upon exercise of stock options (in shares)		9,664
Issuance of common stock upon exercise of stock options	36		36
Stock-based compensation expense	5,209		5,209
Change in unrealized loss on investments, net of tax	(80)			(80)
Net loss	(45,761)				(45,761)
Ending balance (in shares) at Mar. 31, 2024		120,021,274
Ending balance at Mar. 31, 2024	$ 243,766	$ 2	780,950	(95)	(537,091)
Beginning balance (in shares) at Dec. 31, 2024	131,160,842	131,160,842
Beginning balance at Dec. 31, 2024	$ 153,149	$ 2	840,358	1	(687,212)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	0
Stock-based compensation expense	$ 5,681		5,681
Change in unrealized loss on investments, net of tax	(16)			(16)
Net loss	$ (51,890)				(51,890)
Ending balance (in shares) at Mar. 31, 2025	131,160,842	131,160,842
Ending balance at Mar. 31, 2025	$ 106,924	$ 2	$ 846,039	$ (15)	$ (739,102)